by Jason Heaviland | Aug 18, 2026
Metabolomic Profiling of ApoE Deficiency Reveals Altered Lipid Metabolism This application note profiles metabolic alterations associated with ApoE deficiency using matched serum and liver samples from ApoE knockout and wild-type rats. Untargeted metabolomics...
by ODWAdmin | Aug 6, 2026
This data report profiles metabolic alterations associated with ApoE deficiency using matched serum and liver samples from ApoE knockout and wild-type rats. The study identifies significantly altered metabolites, revealing systemic lipid remodeling and disruptions in...
by Jason Heaviland | Jul 8, 2026
Metabolic Profiling of Fuchs Endothelial Corneal Dystrophy This poster, presented by researchers from the Icahn School of Medicine at Mount Sinai, showcases how Next-Generation Metabolomics can reveal metabolic alterations associated with Fuchs endothelial corneal...
by ODWAdmin | May 22, 2026 | Uncategorized
In the fight against cancer, single-agent treatments often hit a wall as tumors adapt and develop resistance. This is especially true for aggressive cancers like non-small-cell lung cancer (NSCLC) with KRAS and LKB1 mutations, a hard-to-treat subtype. These challenges...
by ODWAdmin | May 22, 2026
Metabolomics for Mechanism of Action in Synergistic Cancer Treatments Next-Generation Metabolomics can provide robust, biologically meaningful data for drug combination analysis. Learn more about treatment-induced metabolic reprogramming and targeted combination...
